Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
The company's HIV sales surged 16% during the quarter, setting the scene for its anticipated summer launch of long-acting PREP candidate lenacapivir.
The company's HIV sales surged 16% during the quarter, setting the scene for its anticipated summer launch of long-acting PREP candidate lenacapivir.
